Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety and PK of Dengushield in healthy adults
NCT03883620Phase 1Completed
- Sponsor
- Serum Institute of India
- Start
- Mar 2019
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of VIS513 in dengue fever (7 cohorts), sponsored by Serum Institute of India. Primary endpoints: Proportion of participants with post-injection/infusion adverse events at 4 hours, Proportion of participants with AEs, discontinuations due to AEs, and serious adverse events at 84 days and 1 more. Started Mar 2019; status: completed.
02
Drugs
VIS513
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT03883620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03883620.